Company
Immuron Ltd
ASX:IMC
Immuron Ltd (ASX:IMC, NASDAQ:IMRN) is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
71 stories
Immuron’s strategic investee launches gut health supplement Juvia in Australia
New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut.
Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up
Immuron is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut mediated diseases.
Immuron receives US patent on drug composition to treat Clostridium difficile
Clostridium difficile remains a major medical problem, causing an estimated economic burden of more than US$10 billion globally with 28,000 deaths per year in the US alone.
Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
Phase II clinical study results have revealed excellent safety and tolerability.
Immuron achieves strong sales growth for travellers’ diarrhoea product
The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018.
Immuron concludes promising fatty liver disease clinical study
The company will report top line clinical trial results in Q1 2018.
Immuron set to commence Clostridium Difficile Infection study in Israel
The company’s IMM-529 is a naturally produced biological antibody product
Immuron targets cash injection
The halt will remain in place until Tuesday 13th June 2017.
Immuron looks to NASDAQ
The halt will remain in place until Thursday 1st June 2017.
Immuron gets ready to begin clinical trial of new drug candidate
CDI causes an estimated annual economic cost of more than US$10 billion.
Immuron enrols first patient in paediatric fatty liver trial in the U.S.
Pediatric NAFLD is a progressive form of liver disease.
Immuron watches several high-value NASH related deals
Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.